Michael Sapienza: Amgen’s targeted therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer
Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared on LinkedIn:
“Fewer than one in five people diagnosed with metastatic colorectal cancer survive beyond five years after diagnosis because there are not enough effective treatment options. Today, there is a new option for some of those patients.
I’m pleased to share that the FDA approved Amgen’s targeted combination therapy for the treatment of chemorefractory KRAS G12C-mutated metastatic colorectal cancer.
The Colorectal Cancer Alliance Cancer Alliance applauds this approval. The combination approach is an important breakthrough for patients with KRAS G12C-mutated metastatic colorectal cancer, offering a new beneficial treatment option for patients living with this devastating and challenging disease.”
Michael Sapienza is the Chief Executive Officer of the Colorectal Cancer Alliance. He served as President and Founder of The Chris4Life Colon Cancer Foundation from 2010-2015. He was also a Faculty member at the North Carolina Governor’s School and a Fellow at New World Symphony.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023